HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome - Archive ouverte HAL Access content directly
Journal Articles Autoimmunity Reviews Year : 2018

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

(1, 2) , (3) , (4, 5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (10) , (13) , (14) , (15) , (7) , (16) , (17) , (18) , (16) , (19) , (1) , (20, 21) , (22) , (17) , (23) , (24) , (25) , (26) , (17) , (27, 28) , (6) , (1) , (29) , (30) , (27, 28) , (31) , (32) , (1, 33) , (34) , (35, 36) , (37) , (38, 39) , (40) , (41) , (42) , (43) , (34) , (12) , (44) , (27, 28) , (27, 28) , (45) , (46, 34) , (37) , (10) , (47) , , (46, 34) , (48) , (49) , , (50) , (29) , (17) , (51) , (1) , (52) , (53) , (7) , (54) , (55) , (25) , (25) , (56) , (9) , (57) , (41) , (58) , (59) , (60) , (16)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Sébastien Abad
  • Function : Author
  • PersonId : 774635
  • IdRef : 184462436
Howard Amital
Emmanuel Andres
  • Function : Author
Laurent Arnaud
Bernard Imbert
  • Function : Author
Thierry Martin
Gyorgy Nagy
  • Function : Author
Florence Perrinet
  • Function : Author
Damien Sene
  • Function : Author
  • PersonId : 941139
Loïc Sentilhes
  • Function : Author
  • PersonId : 925211
Jean Sibilia
  • Function : Author
  • PersonId : 948651

Abstract

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3].Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16].Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency.Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial.This trial consists in two parts: a retrospective and a prospective study.The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
Not file

Dates and versions

hal-01936357 , version 1 (27-11-2018)

Identifiers

Cite

Cristina Belizna, Francesca Pregnolato, Sébastien Abad, Jaume Alijotas-Reig, Howard Amital, et al.. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17 (12), pp.1153 - 1168. ⟨10.1016/j.autrev.2018.05.012⟩. ⟨hal-01936357⟩
1547 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More